We are delighted that Bob has joined Venomix, said John L. McIntyre, president and chief operating officer of Venomix. He has a broad background in developing new chemical entities – just what we need to bring our spider venom peptides to market as commercial insecticides.
At Pfizer/Parke-Davis, nine drug candidates were identified with five progressing to clinical trials, including a follow-on candidate to Lipitor under Kennedy leadership. He received his doctorate in organic chemistry from Virginia Polytechnic and State University. Upon completing a postdoctoral fellowship at the Massachusetts Institute of Technology, he became an assistant professor at Columbia University.
